In contrast, sPD-L1 emerges as a robust marker for disease monitoring and prognosis, particularly in immunogenic tumors such as renal cell carcinoma, supported by our data and corroborated by the existing literature and unpublished findings in melanoma. This evidence concerns the gene SPDL1 and renal cell carcinoma.